Immunotherapy drug shows promise for tough brain tumor
NCT ID NCT03279692
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the immunotherapy drug pembrolizumab in 26 people with high grade meningioma that came back or remained after treatment. The goal was to see if the drug could stop the tumor from growing for at least 6 months. Participants received pembrolizumab and had regular MRI scans to check their response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.